Bayer Aspirin For Moscow
Bayer AG has started packing its Aspirin analgesic in Moscow to supply the Russian market. Initial production of 20 million 0.5mg aspirin tablets per year has started on the basis of a contract signed in October 1993 between the Swiss-Russian joint venture Suramed and the Russian drugmaker MBA.
Meantime, there is speculation in the USA that the name of Bayer's subsidiary there, Miles Laboratories, will be changed to Bayer, now that the German company has bought back the rights to that title from Sterling Winthrop via its deal with SmithKline Beecham (Marketletter September 19 and pages 24-25).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze